Novartis begins filings for cannabis-based Sativex in Middle East 22 November 2011 / Sukaina Virji
Novartis will target filings in the Middle East next as part of its licence agreement with GW Pharmaceuticals for the cannabis-based multiple sclerosis-related spasticity treatment Sativex. These are slated for the first half of 2012, GW's managing director Justin Gover told Scrip.
Más

Ver también:



No hay comentarios:
Publicar un comentario